We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Donated Blood Could Be Transformed Into Universal Type

By LabMedica International staff writers
Posted on 10 May 2015
Blood transfusions are critically important in many medical procedures, but the presence of antigens on erythrocytes means that careful blood-typing must be carried out prior to transfusion to avoid adverse and sometimes fatal reactions following transfusion.

Every day, thousands of people need donated blood, but only blood without A- or B-type antigens, such as type O, can be given to all of those in need, and it's usually in short supply. More...
However an efficient way to transform A and B blood into a neutral type that can be given to any patient has been reported.

Scientists at the University of British Columbia (Vancouver, BC, Canada) working with other Canadian and French investigators studied how to enzymatically remove the terminal N-acetylgalactosamine or galactose of A- or B-antigens, respectively, which would yield universal O-type blood. They started with the family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 which cleaves the entire terminal trisaccharide antigenic determinants of both A- and B-antigens from some of the linkages on red blood cell surface glycans. Through several rounds of evolution, they developed variants with vastly improved activity toward some of the linkages that are resistant to cleavage by the wild-type enzyme.

The investigators fine-tuned one of those enzymes and improved its ability to remove type-determining sugars by 170-fold, rendering it antigen-neutral and more likely to be accepted by patients regardless of their blood type. The authors concluded that the resulting enzyme effects more complete removal of blood group antigens from cell surfaces, demonstrating the potential for engineering enzymes to generate antigen-null blood from donors of various types. In addition to blood transfusions, the scientists say their advance could potentially allow organ and tissue transplants from donors that would otherwise be mismatched. The study was published on April 14, 2015, in the Journal of the American Chemical Society.

Related Links:

University of British Columbia 



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.